We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

ACB A Randomized Study of 2.5ug/kg/Day vs. 5ug/kg/Day Dose of G-CSF After High Dose Chemotherapy Followed by Autologous Peripheral Blood Stem Cell/Marrow Transplant Recipients FILE#17159

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00168168
First Posted: September 15, 2005
Last Update Posted: February 9, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
AHS Cancer Control Alberta
September 14, 2005
September 15, 2005
February 9, 2010
July 2003
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00168168 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
ACB A Randomized Study of 2.5ug/kg/Day vs. 5ug/kg/Day Dose of G-CSF After High Dose Chemotherapy Followed by Autologous Peripheral Blood Stem Cell/Marrow Transplant Recipients FILE#17159
ACB A Randomized Study of 2.5ug/kg/Day vs. 5ug/kg/Day Dose of G-CSF After High Dose Chemotherapy Followed by Autologous Peripheral Blood Stem Cell/Marrow Transplant Recipients FILE#17159
Evaluate recovery time on 2.5 mg/Kg/day dose of G-CSF versus 5 mg/Kg/day dose.
Not Provided
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double
Primary Purpose: Treatment
Peripheral Stem Cell/Marrow Transplant
Drug: G-CSF/Filgrastim
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
60
February 2007
Not Provided

Inclusion Criteria:

  • over age 18
  • autologous stem cell/marrow transplant candidate in MM, lymphoma, AMG and testicular

Exclusion Criteria:

  • age below 18 years
  • sensitive to G-CSF
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
 
NCT00168168
HE-10-0053
Not Provided
Not Provided
Not Provided
Not Provided
Alberta Health Services
Not Provided
Principal Investigator: Meluka Game, MD AHS Cancer Control Alberta
AHS Cancer Control Alberta
April 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP